| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a new intensifier of the antitumour effect, which is a uracil derivative of the general formula (I) or its pharmaceutically acceptable salt. In the general formula(I) X represents a C-alkylene group, and wherein one of methylene groups making an alkylene group is optionally substituted by an oxygen atom; Rrepresents a hydrogen atom or a C-alkyl group; Rrepresents a hydrogen atom or a halogen atom; and Rrepresents a C-alkyl group, C-alkenyl group, C-cycloalkyl group, (C-cycloalkyl)-C-alkyl group, halogen-C-alkyl group or a 5-6-merous saturated heterocyclic group with an oxygen atom as a heteroatom, a uracil derivative presented by the following formula (I). The invention also refers to a method for potentiating the antitumour action or a method of treating tumours, involving administering an effective amount of a combination of the above uracil derivative or its pharmaceutically acceptable salt and an antimetabolite in an effective amount. The antimetabolite represents an agent specified in 5-fluoruracil (5-FU), potassium tegafur//oteracil (TS-1), tegafur/uracil (UFT), capecitabin, 5-fluor-2'-deoxyuridine (FdUrd) and Pemetrexed.EFFECT: preparing the intensifier of the antitumour effect.18 cl, 10 dwg, 10 tbl, 67 ex |
